Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01656447 · ClinicalTrials.gov registry record
Scleroderma Registry & Repository at the Hospital for Special Surgery
A clinical trial of Scleroderma, sponsored by Hospital for Special Surgery, New York.
- Recruiting
- Registry status
- 300
- Enrollment target
- 1
- Study location
NCT01656447: Recruiting study of Scleroderma, sponsored by Hospital for Special Surgery, New York.
NCT01656447 is a study of Scleroderma that is actively recruiting participants, run by Hospital for Special Surgery, New York. The registered enrollment target is 300 participants, below the 389-participant average among 23 other Scleroderma trials with a reported enrollment target (23% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01656447, a study of Scleroderma, is actively recruiting participants, sponsored by Hospital for Special Surgery, New York.
- RECRUITING
- Registry status
- 300 participants
- Enrollment target
- 1
- Study location
Study Summary
The overall objective of the Scleroderma Registry is to support and promote the basic science and clinical research of this complex rheumatic disease at the Hospital for Special Surgery (HSS). The registry facilitates our understanding of the clinical features, pathobiology, genetics of Scleroderma. This will ultimately lead to a potential treatment for this currently untreatable condition.
Primary Outcome
Physician score of skin thickening over 17 areas of the body.
Conditions Studied
Study Locations (1)
New York
- Hospital for Special Surgery - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2006-08 |
| Est. Completion | 2030-01 |
What NCT01656447 shows while recruiting
NCT01656447 is an observational study that tracks outcomes without assigning an intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, below the 389-participant average among 23 other Scleroderma trials with a reported enrollment target (23% lower).
The record links to 1 condition, with Scleroderma appearing as the primary indexed condition, and to 0 interventions.
NCT01656447 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT01656447 about?
NCT01656447 is a clinical study titled "Scleroderma Registry & Repository at the Hospital for Special Surgery". The overall objective of the Scleroderma Registry is to support and promote the basic science and clinical research of this complex rheumatic disease at the Hospital for Special Surgery (HSS). The registry facilitates our understanding of the clinical features, pathobiology, genetics of Scleroderma....
What is the current status of trial NCT01656447?
This trial is currently recruiting. The enrollment target is 300 participants. The study started on 2006-08. Estimated completion is 2030-01.
What conditions does trial NCT01656447 study?
This clinical trial studies the following conditions: Scleroderma.
Who is sponsoring clinical trial NCT01656447?
This trial is sponsored by Hospital for Special Surgery, New York, which has 194 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01656447 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Scleroderma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01656447's enrollment target sits among peer trials
300 7th of 23 higher than 16 of 23 other Scleroderma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Scleroderma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Rheumatology Diet Study
RECRUITING
-
Maternal Autoimmune Disease Research Alliance (MADRA) Registry
RECRUITING
-
RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis
RECRUITING · Phase 1
-
Platform Clinical Study for Conquering Scleroderma
RECRUITING · Phase 2
-
AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.
RECRUITING · Phase 2
-
Brain Boost Program to Improve Cognitive Function in People With Systemic Sclerosis
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00353483 · 300 participants
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
- NCT00588185 · 300 participants · NA
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
- NCT00682032 · 300 participants · NA
The Effect of Beta-glucan in Non-Small Cell Lung Cancer
- NCT00870064 · 300 participants · NA
The Treatment of Type I Open Fractures in Pediatrics
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia